Dalsiclear (Daclatasvir) is specifically indicated for use with sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) of genotype 1, 3, or 4
The other medications used in combination include sofosbuvir, ribavirin, and interferon, vary depending on the virus type and whether the person has cirrhosis. Dalsiclear (Daclatasvir) stops HCV viral RNA replication and protein translation by directly inhibiting HCV protein NS5A. NS5A is critical for HCV viral transcription and translation, Natdac (Daclatasvir) is supplied as tablets for oral administration.
It is taken by mouth once a day. The recommended dose is 60 mg taken orally once daily with or without food in combination with sofosbuvir. The recommended treatment duration is 12 weeks. Dose modification: reduce dosage to 30 mg once daily with strong CYP3A inhibitors and increase dosage to 90 mg once daily with moderate CYP3A inducers.
Dose modifications are made with concomitant use of daclatasvir and drugs that affect CYP3A or p-gp. When taking daclatasvir with non-nucleoside reverse transcriptase inhibitors, the dose of daclatasvir is increased to overcome CYP3A induction.
With daclatasvir, sofusbivir, and ribavirin the most common side effects are headache, feeling tired, nausea, and red blood cell breakdown. It should not be used with St. John's wort, rifampin, or carbamazepine. It works by inhibiting the HCV protein NS5A. It is on the World Health Organization's List of Essential Medicines.
Portion 'A' First Floor,
Old No. 131, New No. 50,
Pedariyar Koil Street,
Seven Wells, Chennai - 600001.